ArticleOncotarget2016
Methylation-regulated miR-124-1 suppresses tumorigenesis in hepatocellular carcinoma by targeting CASC3.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Role of MicroRNA-124 as a Prognostic Factor in Multiple Neoplasms: A Meta-Analysis.Disease markers · 2019Pooled it
- Decoding clone evolution in HER2 amplified breast cancer through single-cell and spatial transcriptomics analysis of copy number variations.Scientific reports · 2026Article
- MLN51 (Metastatic Lymph Node Gene 51)/CASC3 (Cancer Susceptibility Candidate Gene 3), A Putative Tumour Suppressor in Breast Cancer, the Clinical and Therapeutic Connections.Breast cancer (Dove Medical Press) · 2026Article
- Gene regulation through exon junction complex modularity.Nature structural & molecular biology · 2025Review
- Smurf2 enhances ubiquitin-mediated degradation of CASC3 and attenuates leukemia progression.iScience · 2025Article
- Targeting microRNA methylation: Innovative approaches to diagnosing and treating hepatocellular carcinoma.Non-coding RNA research · 2025Review
- The Epigenetic Role of miR-124 in HIV-1 Tat- and Cocaine-Mediated Microglial Activation.International journal of molecular sciences · 2022Article
- Article
- miR-660 promotes liver cancer cell proliferation by targeting PPP2R2A.Experimental and therapeutic medicine · 2021Article
- Tumor Suppressive Effects of miR-124 and Its Function in Neuronal Development.International journal of molecular sciences · 2021Review
- The construction and validation of an RNA binding protein-related prognostic model for bladder cancer.BMC cancer · 2021Article
- MicroRNA-124: An emerging therapeutic target in cancer.Cancer medicine · 2019Review
- Article
- Regulatory Network of Two Tumor-Suppressive Noncoding RNAs Interferes with the Growth and Metastasis of Renal Cell Carcinoma.Molecular therapy. Nucleic acids · 2019Article
- Expression and gene regulation network ofAging · 2019Article
- Involvement of anti-tumorOncotarget · 2018Article
- Epigenetic Promoter DNA Methylation of miR-124 Promotes HIV-1 Tat-Mediated Microglial Activation via MECP2-STAT3 Axis.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2018Article
- MicroRNA-124-3p expression and its prospective functional pathways in hepatocellular carcinoma: A quantitative polymerase chain reaction, gene expression omnibus and bioinformatics study.Oncology letters · 2018Article
- Hypermethylation of NF-κB-Activating Protein-Like (NKAPL) Promoter in Hepatocellular Carcinoma Suppresses Its Expression and Predicts a Poor Prognosis.Digestive diseases and sciences · 2018Article
- circHIPK3 regulates cell proliferation and migration by sponging miR-124 and regulating AQP3 expression in hepatocellular carcinoma.Cell death & disease · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was to investigate the roles and mechanisms of miR-124-1 in hepatocellular carcinoma (HCC). We analyzed the expression of miR-124-1 in human HCC tissues and cell lines. Luciferase reporter assays were used to analyze the target of miR-124-1. Human HCC cell lines were transduced with lentiviruses expressing miR-124-1, and proliferation and colony formation were analyzed. The growth of human HCC cells overexpressing miR-124-1 was assessed in nude mice. The expression of p38-MAPK, JNK, ERK and related signaling molecules was detected by western blotting and immunohistochemistry. Our results showed that miR-124-1 levels were reduced in HCC tissues and cell lines compared with those in adjacent non-cancer tissues and normal liver cell lines respectively. Downregulation of miR-124-1 in HCC cell lines were attributed to hypermethylation of its promoter region. Overexpression of miR-124-1 inhibited HCC cell proliferation in vitro, whereas miR-124-1 was correlated with clinicopathological parameters of HCC patients. HCC cell-mediated overexpression of miR-124-1 in nude mice suppressed tumor growth. Cancer susceptibility candidate 3 (CASC3) was identified as a direct target of miR-124-1 by computational analysis and experimental assays. MiR-124-1-mediated downregulation of CASC3 resulted in the inactivation of p38-MAPK, JNK and ERK. Our findings provide potential new targets for the prevention or treatment of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.